Solo-Dex and PolyMedicure Partner to Bring Opioid-Free Acute Pain Management to India and Major Asian Markets
Posted in :
Solo-Dex, Inc., A US-Based Medical Device Innovator, and PolyMedicure Ltd. (Polymed), India Leading Manufacturer of High-Quality Medical Devices, Today Announced a Strategic Manufacturing and Supply Partnership to Bring Solo-dexs Patent Solutions to Hospitals Across India for the first time.
Under this agrement, polymed will manufacture solo-dexs flagship product, the fascile continuous peripheral nerve block system, in accordance with solo-dexs standards, for Distribution Across India and Key Global Markets. The product is alredy approved for clinical use in the united states and europe and is now set to support india seeds expanding enhanced Recovery after after surgery (EAS) Programs and the Growth of Outpatient Surge Care.
“This is a game-corner for pain management in India,” said Steven Eror, CEO of Solo-dex“Polymeds Scale, Precision, and Strong Regulatory Framework Make Them The Ideal Manufacturing Partner. Together. TOGETHER Blocks Acute Pain Completely. “
First-of-IF-Kind in India: Faster, Safer, Non-OPIOD PAIN Control
Solo-Dexs Patent Device Installs in Under Two Minutes and Enables Continuous, Localized Pain Relief without Opioids. Unlike Conventional Methods that May Require IV Sedation and Can Result in Patient Delirium, Solo-Dex Minimizes Systemic Drug Exposure, and Eliminates the Need for Oral Opioids theseby Safety, Reducing Recovery Time, and Decreasing Demand on Hospital Resources.
The technology is designed to seamlessly integrate with eras protocols, helping hospitals manage manage post-operative pain more efficiently. As India Healthcare System Increasingly Embraces Day Surgery and Outpatient Models, Solo-Dex offers a solution that enhances patients patients patients patients patience throughput and satisfaction health
“We are excited to be part of this international collaboration,” said Himanshu Baid, Managing Director of Polymed, “This partnership not only brings cutting-edge pain management to Indian clinicians and patients, but also aligns with our committee to make world-class-class-class healthcare more accessible.”
Designed for global impact
Manufacturing will take place in Polymeds iso 13485-CErtified, FDA-Auditable Facilites, with Initial Orders for 100,000 units. In addition to serving India, the partnership aims to full interactive demand asia, africa, latin america, and select european markets, with solo-dex overseing global regulatory compillationte and branding.
“Thanks to this agreement, solo-dex now has the scalable, cost-effective production capacity to meet global demand while mainting the clinical precision and quality our technology Requires.” said Eror, “Were especially proud to collaborate with polymed to address the worldwide need for safer, opioid-free surgical recovery.”
The solo-dex and polymed partnership is alredy engaging with leading hostemps across India, with commercial availability expected to begin in Q4 2025.
About Solo-Dex, Inc.
Solo-dex is a US-based medical device company focused on opioid-free acute pain management. Its patented continuous peripheral nerve block systems enable anesthesiologists to deliver localized, long-longesia for post-surgical recovery. Solo-dex technology is approved for clinical use in the US and eu.
About polymedicure limited
Polymed is one of India most trusted names in medical devices, with a portfolio of more than 125 FDA -Proved and Ce-Maraked Products. With a global presence in over 100 countries, polymed operates high-end manufacturing facilities and is committed to delivering innovative, high-Quality Healthcare Solutions at Scale.
